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ABSTRACT 
Aims: To continually evaluate the association between cardiovascular drug exposure and COVID-19 
clinical outcomes (susceptibility to infection, disease severity, hospitalization, hospitalization length, 
and all-cause mortality) in patients at risk of/with confirmed COVID-19.  
Methods: Eligible publications were identified from >500 databases on 1-Nov-2020. One reviewer 
extracted data with 20% of the records independently extracted/evaluated by a second reviewer.  
Results: Of 52,735 screened records, 429 and 390 studies were included in the qualitative and 
quantitative syntheses, respectively. The most-reported drugs were angiotensin-converting enzyme 
inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) with ACEI/ARB exposure having borderline 
association with confirmed COVID-19 infection (OR 1.14, 95% CI 1.00–1.31). Among COVID-19 
patients, unadjusted estimates showed that ACEI/ARB exposure was associated with hospitalization 
(OR 1.76, 1.34–2.32), disease severity (OR 1.40, 1.26–1.55) and all-cause mortality (OR 1.22, 1.12–
1.33) but not hospitalization length (mean difference -0.27, -1.36; 0.82 days). After adjustment, 
ACEI/ARB exposure was not associated with confirmed COVID-19 infection (OR 0.92, 0.71–1.19), 
hospitalization (OR 0.93, 0.70–1.24), disease severity (OR 1.05, 0.81–1.38), or all-cause mortality (OR 
0.84, 0.70–1.00). Similarly, subgroup analyses involving only hypertensive patients revealed that 
ACEI/ARB exposure was not associated with confirmed COVID-19 infection (OR 0.93, 0.79–1.09), 
hospitalization (OR 0.84, 0.58–1.22), hospitalization length (mean difference -0.14, -1.65; 1.36 days), 
disease severity (OR 0.92, 0.76–1.11) while it decreased the odds of dying (OR 0.76, 0.65–0.88). A 
similar trend was observed for other cardiovascular drugs. However, the validity of these findings is 
limited by a high level of heterogeneity and serious risk of bias. 
Conclusion: Cardiovascular drugs are not associated with poor COVID-19 outcomes in adjusted 
analyses. Patients should continue taking these drugs as prescribed. 
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BACKGROUND 
Coronavirus disease 2019 (COVID-19) was first reported on 8 December 2019 in Wuhan, Hubei 
province, China.1 It is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
which infects cells through the human angiotensin-converting enzyme 2 (ACE2) receptor.2 It was 
designated a pandemic by the World Health Organization on 11 March 20203 and has since affected 
192 countries/regions, more than 112 million patients and led to close to 2.5 million deaths (as of 24 
February 20214).  To put it into context, cardiovascular diseases such as ischemic heart disease, 
stroke and heart failure remain the leading causes of global deaths, being responsible for an 
estimated 17·8 million deaths in 2017.5 The interaction between COVID-19 and cardiovascular 
disease appears complex and bi-directional with cardiovascular disease increasing susceptibility to 
SARS-CoV-2 infection or COVID-19 severity and at the same time COVID-19 causing injury to the 
cardiovascular system in some patients.6,7 Consequently, the relationship between COVID-19 and 
cardiovascular drugs is of interest because: a) patients with increased susceptibility to SARS-CoV-2 
infection may be taking these drugs, b) they may alleviate cardiovascular injury caused by COVID-19, 
and c) cardiovascular drugs such as angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin 
receptor blockers (ARBs) may play a direct role in COVID-19 pathology.2  
Recent systematic reviews, including a living systematic review,8 have characterized the relationship 
between COVID-19 outcomes and cardiovascular drugs. These reviews have, however, focused on 
ACEIs and ARBs. However, being a novel disease, a lot is still unknown about COVID-19 which makes 
a broader systematic review (in terms of the drugs studied) necessary. Moreover, there are 
emerging reports that other drug classes such as anticoagulants, calcium channel blockers and 
statins could be beneficial.9-11 Additionally, many cardiovascular disease patients are on combination 
therapies and a broader review may facilitate understanding of the interplay between the different 
classes of cardiovascular drugs. Lastly, evidence in this field is rapidly evolving which means that 
recently published reviews soon become outdated. To provide more comprehensive and up-to-date 
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evidence, we have conducted a systematic review and meta-analysis to evaluate all the current 
evidence on the association between cardiovascular drug exposure and COVID-19 clinical outcomes 
in patients at risk of/with confirmed COVID-19. Due to the rapidly evolving nature of this field, we 
will periodically update this baseline review for up to two years to reflect emerging evidence. 
 
METHODS 
A predefined protocol (PROSPERO: CRD4202019128312), based on the principles of the Cochrane 
Handbook for Systematic Reviews of Interventions13 with living systematic review considerations14 
was followed. This report adheres to the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA, Table S1). 
Identification of studies 
A final search of the University of Liverpool’s DISCOVER platform (which links, through EBSCOhost, to 
sources from >500 databases including MEDLINE, Table S2), several preprint servers, COVID-19 
specific databases (such as the COVID-19 Clinical Trials registry and the World Health Organization 
database of COVID-19 publications), and other registries/results databases (such as ClinicalTrials.gov 
and the International Clinical Trials Registry Platform) was undertaken on 1st November 2020 using 
medical subject headings and text words related to “cardiovascular drugs” and “COVID-19” as 
previously detailed.12,15 A separate MEDLINE search15 was conducted to ensure that the DISCOVER 
search was retrieving all eligible records. Because we separately searched for grey literature, the 
DISCOVER search was limited to studies published in academic journals. EndNote (version X9)16 was 
used to upload DISCOVER search results and de-duplicate studies by information regarding author, 
year of publication, title, and reference type. Lastly, lists of references from the identified studies 
and previous systematic reviews were hand-searched to identify additional eligible articles. 
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Selection criteria 
This review included observational (e.g. retrospective or prospective cohort and case-control 
studies) and interventional (e.g. randomised controlled trials) studies that: a) reported 
cardiovascular drug exposure (cardiovascular drug classes/sub-classes (Table S3) were those derived 
from Chapter 2 (“Cardiovascular system”) of the British National Formulary17), and b) investigated 
the association between cardiovascular drug exposure and COVID-19 clinical outcomes (outlined 
below). Case series were included if they reported at least 5 patients. Unless translated text could be 
obtained, non-English studies were excluded. We did not exclude any studies based on publication 
status. 
Outcomes 
COVID-19 clinical outcomes included susceptibility to infection (for those at risk of COVID-19), and 
disease severity,15 hospitalization, hospitalization length, and all-cause mortality (for those with 
COVID-19). 
Study selection and data extraction  
One reviewer (IGA) screened titles and abstracts of all retrieved bibliographic records according to 
eligibility. In addition to conducting an independent MEDLINE search, a second reviewer (SP) 
independently screened 20% of the records to check for consistency. Full texts of potentially eligible 
studies were retrieved, a data extraction form developed and piloted in a subset of ten randomly 
selected papers and used to extract relevant information (related to study design, patient 
characteristics, cardiovascular drugs, COVID-19 outcomes, and study quality). Data from all eligible 
studies were extracted and summarized by one reviewer (IGA). As a quality control measure, a 
second reviewer (SP or RMT) independently extracted and evaluated 20% of the records, between 
them, to ascertain consistency. Any disagreements were resolved by consensus. 
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Assessment of study quality 
To assess the quality of each included study, the modified Oxford Centre for Evidence-based 
Medicine for ratings of individual studies was used as detailed in the protocol12 and Table S4. Again, 
IGA evaluated all records with SP and RMT independently evaluating 20% of the records between 
them, and disagreements being resolved by consensus.  
Data synthesis 
Where ≥2 studies reporting on the same exposure-outcome combination were reported, effect 
estimates were pooled by way of random-effects meta-analyses (inverse-variance method for effect 
size, DerSimonian-Laird estimator for variance) using R version 3.6.1 (R meta package18). 
Odds/hazards/risk ratios and mean differences (with 95% confidence intervals) were generated for 
dichotomous and continuous outcomes, respectively. Both unadjusted (or in the case of binary 
outcomes, count data, which is preferred to unadjusted odds ratios as it provides more reliable 
estimates19) and adjusted estimates were extracted and pooled separately. Where there was more 
than one adjusted estimate, the estimate adjusting for the most covariates was preferred. Since 
different studies adjust for different covariates, we did not limit our inclusion criteria to a given set 
of covariates. Where median values and ranges/interquartile ranges were provided (for example for 
length of hospitalization), they were used to estimate the mean values and standard deviations.20 
Where necessary, means and standard deviations were combined using formulae available in the 
Cochrane Handbook.21  
Where two or more studies used the same dataset for a given exposure-outcome combination 
(identified with reference to authors and their affiliations, recruitment sites, recruitment periods 
and patient eligibility criteria), then peer-reviewed publications and those reporting a larger number 
of patients were preferred. In instances where it was not obvious if the included patients were the 
same but there was a possibility of overlap (e.g. studies recruiting from similar sites with overlapping 
recruitment periods but different authors), only one of these studies (the one with the largest 
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sample size) was included in the primary meta-analyses. Because of the uncertainty with identifying 
studies with overlapping data, pooled estimates in which all studies, regardless of any overlapping, 
were included are also reported. Forest plots were prepared for each exposure-outcome 
combination. Studies that could not be pooled due to being the only ones reporting on an exposure-
outcome combination were also included as part of qualitative synthesis. 
Heterogeneity measures 
The magnitude of inconsistency in the study results was assessed by visually examining forest plots 
and considering the I2 statistic. Arbitrarily-defined categories of heterogeneity were: I2 <30%, low; I2 
=30–70%, moderate; and I2 >70 %, high.  
Publication bias 
Where enough (≥10) studies were available for a given exposure-outcome combination, publication 
bias was assessed using the linear regression test of funnel plot asymmetry (Egger’s test, 
implemented using the metabias function in the R meta package18). A p-value <0.1 was considered 
to suggest the presence of publication bias. When asymmetry was suggested by a visual assessment, 
we performed exploratory analyses to investigate and adjust for it (trim and fill analysis) using the 
trimfill function (R metafor package22). 
Subgroup analyses 
Based on our preliminary meta-regression results,15 we conducted sub-group analyses only based on 
treatment of hypertension. 
Confidence in cumulative evidence 
The strength of the body of evidence and the quality and strength of recommendations was 
assessed according to the GRADE (Grading of Recommendations, Assessment, Development and 
Evaluations) criteria.23 
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Nomenclature of Targets and Ligands 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 




Study selection and characteristics 
Of the 52,735 titles screened, 429 and 390 studies were included in the qualitative and quantitative 
syntheses respectively (Figure 1). The characteristics of the included studies are shown in Table S5 
while Spreadsheet S1 contains quantitative data for all included papers. Of the 429 studies, more 
than a third (n = 156, 36%) were preprints. Almost all studies (n = 427, >99%) were observational 
with only two (<1%) studies25,26 being interventional in nature (open-label randomized control trials, 
RCTs). Moreover, the two RCTs both conducted retrospective/non-pre-specified interim analyses of 
their currently recruited trial participants. Based on the modified Oxford Centre for Evidence-based 
Medicine for ratings of individual studies, all pooled estimates received quality ratings of either 3 or 
4 for including mostly observational studies (case-controls, respective cohorts, case series and/or 
cross-sectional studies).  
The most commonly reported drug exposure was with angiotensin-converting enzyme inhibitors 
(ACEIs)/angiotensin receptor blockers (ARBs) (ACEI/ARBs), which therefore became the main focus. 
This report is additionally restricted to the major cardiovascular drug classes (ARBs, ACEIs, 
anticoagulants, antiplatelets, beta blockers, calcium channel blockers, diuretics and lipid modifying 
drugs) and for exposure-outcome combinations that were reported by at least 10 studies. 
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Meta-analysis  
Table 1, Figures 2–3 and Figures S1–36 summarise the pooled estimates for the associations 
between all reported cardiovascular drug exposures and the various COVID-19 clinical outcomes. 
The text below is focused on the most reported drug (ACEI/ARB) exposure. 
Susceptibility to infection (patients at risk of COVID-19) 
Fifty-nine studies reported count data and/or crude odds ratios (OR) for the association between 
ACEI/ARB exposure and susceptibility to infection (Figure S1). Eleven studies were removed to 
minimize the inclusion of studies with overlapping data. The primary meta-analysis (48 studies, 
10,522,649 participants) revealed that ACEIs/ARBs had borderline association with confirmed 
COVID-19 infection (pooled unadjusted OR 1.14, 95% CI 1.00–1.31, I2=97%, Figure 2). The linear 
regression test of funnel plot asymmetry (Egger’s test, p = 0.18) was not significant (funnel plot in 
Figure S1). The pooled estimate was no longer statistically significant when analysis was restricted to 
only hypertensive patients (n = 9 studies, OR 0.93, 95% CI 0.79–1.09, I2=82%, Figure 3). Sixteen 
studies reported adjusted or propensity score–weighted odds ratios (pooled adjusted OR 0.92, 95% 
CI 0.71–1.19, I2=85%), six studies reported adjusted hazards ratios (pooled adjusted HR 0.88, 95% CI 
0.75–1.04, I2=76%) while adjusted risk ratios were obtained from seven studies (pooled adjusted RR 
0.99, 95% CI 0.86–1.14, I2=76%) (Figure S1). Except for diuretics (unadjusted estimates), none of the 
other cardiovascular drug exposures (including ACEIs and ARBs assessed separately) were associated 
with susceptibility to infection as detailed in Table 1. 
Hospitalization (COVID-19 patients) 
Thirty-one studies explored the association between being hospitalized and being on ACEIs/ARBs 
(Figure S10). When four studies were excluded to reduce potentially overlapping data, ACEIs/ARBs 
were associated with higher odds of hospitalization (pooled unadjusted OR 1.76, 95% CI 1.34–2.32, 
I2=95%, Figure 2) in a total of 63,132 patients. Egger’s test was not significant (p-value = 0.26). Four 
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studies included only hypertensive patients and for these, the pooled estimate lost statistical 
significance (0.84, 95% CI 0.58–1.22, I2=66%, Figure 3). The pooled adjusted odds ratio (11 studies) 
was not statistically significant at 0.93 (95% CI 0.70–1.24, I2=62%), a result which was similar to the 
pooled adjusted hazards ratio (1.08, 95% CI 0.90–1.28, I2=63%, 4 studies). Other cardiovascular drugs 
were also associated with higher odds of hospitalization in unadjusted, but not adjusted, estimates 
(Table 1). 
Hospitalization length (COVID-19 patients) 
Twenty-seven studies reported length of hospitalization (Figure S17). Eighteen studies were 
excluded from the primary analysis because some had potentially overlapping data while others 
included patients who were deceased/still admitted. For the nine included studies (1,697 patients), 
ACEIs/ARBs were not significantly associated with longer hospitalization length (mean difference -
0.27, 95% CI -1.36; 0.82 days, I2=24%, Figure 2). When six studies that included only hypertensive 
patients were pooled, the result was similar (mean difference -0.14, 95% CI -1.65; 1.36 days, I2=0%, 
Figure 3). This outcome was also assessed for anticoagulant drug exposure, with unadjusted 
estimates being statistically non-significant (Table 1). 
Severity (COVID-19 patients) 
One hundred sixty-five studies reported the association between ACEIs/ARBs and severity outcomes 
(Figure S19). Thirty-three studies were excluded due to having potentially overlapping data which 
resulted in a primary meta-analysis of 132 studies (182,841 patients) in which ACEIs/ARBs were 
associated with higher odds of severe disease (pooled OR 1.40, 95% CI 1.26–1.55, I2=87%, Figure 2). 
Publication bias assessment revealed funnel plot symmetry (Egger’s test p = 0.69, Figure S19). Sub-
group analysis based on use in hypertension (38 studies) produced pooled estimates that were no 
longer statistically significant (OR 0.92, 95% CI 0.76–1.11, I2=72%, Figure 3). Adjusted odds ratios 
were obtained from 54 studies (pooled adjusted OR 1.05, 95% CI 0.81–1.38, I2=85%), hazard ratios 
were obtained from 14 studies (pooled adjusted HR 0.84, 95% CI 0.65–1.10, I2=75%) while risk ratios 
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were obtained from 8 studies (pooled adjusted RR 1.53, 95% CI 0.54–4.31, I2=97%) (Figure S19). 
Other cardiovascular drugs were associated with higher odds of severe disease in the unadjusted 
estimates, with statistical significance being lost when subgroup analyses or adjusted estimates were 
considered (Table 1).   
All-cause mortality (COVID-19 patients) 
One hundred sixty-three studies reported the association between ACEI/ARB exposure and all-cause 
mortality (Figure S28). Because some studies had potentially overlapping datasets, only 131 (188,941 
patients) were included in the primary meta-analysis with ACEIs/ARBs being associated with higher 
odds of all-cause mortality (pooled OR 1.22, 95% CI 1.12–1.33, I2=83%, Figure 2). Egger’s test was 
statistically significant (p < 0.10, funnel plot in Figure S28). The trim and fill random effects analysis 
method however showed that missing trials neither changed the direction of the pooled effect 
estimate nor affected its statistical significance (Figure S28). When analysis was restricted to only 
hypertensive patients (39 studies), ACEI/ARB exposure became protective (pooled OR 0.76, 95% CI 
0.65–0.88, I2=62%, Figure 3). The pooled adjusted odds ratio (48 studies) was 0.84 (95% CI 0.70–
1.00, I2=66%), pooled adjusted hazards ratio (27 studies) was 0.76 (95% CI 0.61–0.95, I2=78%) while 
the pooled adjusted risk ratio (10 studies) was 0.71 (95% CI 0.46–1.09, I2=68%). Other cardiovascular 
drugs were associated with higher odds of all-cause mortality in the unadjusted estimates but this 
was lost when only hypertensive patients were considered (Table 1). Except for diuretics, statistical 
significance was lost for other cardiovascular drugs when adjusted ORs were pooled. When adjusted 
hazards ratios were considered, only beta-blockers remained associated with higher odds of all-
cause mortality. On the other hand, ACEIs, antiplatelets, calcium channel blockers and diuretics were 
not associated with all-cause mortality while ARBs, anticoagulants and lipid-modifying drugs 
decreased the odds of dying. Lastly, statistical significance was lost for other drug classes except for 
anticoagulants when adjusted risk ratios were pooled (Table 1). 
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DISCUSSION 
We have conducted a systematic review and meta-analysis to evaluate the current evidence on the 
influence of cardiovascular drugs on five COVID-19 clinical outcomes. The most reported drug classes 
were angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) with 
ACEI/ARB exposure having borderline association with confirmed COVID-19 infection, which is 
similar to a previous estimate by Xu et al. (1.13, 95% CI, 1.05 to 1.22, n = 23 studies).27 Among 
COVID-19 patients, ACEI/ARB exposure was associated with hospitalization, disease severity, and all-
cause mortality but not hospitalization length. Xu et al.27 reported similar results for hospitalization 
length (mean difference -0.04 days, 95%CI -0.19 to 0.11, n = 11 studies) and disease severity (OR 
1.28, 95%CI 1.06 to 1.54, n = 58 studies) but not mortality (OR 1.06, 95%CI 0.85 to 1.31). Our study, 
which included 131 studies for the mortality outcome, is however more comprehensive than Xu et 
al.’s which included only 44 studies for the same outcome. With a higher rate of hospitalization and 
more severe disease, one would expect longer hospital stay, which makes our results seem counter-
intuitive. However, the hospitalization length outcome excluded patients who died or those who 
were still hospitalized by the time of analysis, which may have contributed to the observed 
discrepancy. A reason such patients were excluded in the primary analysis is that shorter 
hospitalization length is a desirable outcome if a patient is discharged but a shorter hospitalization 
length that results in death isn’t. Nevertheless, an analysis that included studies with patients who 
were deceased/still admitted produced a similar result (mean difference -0.31 days, 95%CI -0.56 to 
1.17, n = 27 studies). It is also important to note that these results are from pooling unadjusted 
estimates which did not account for confounding factors such as cardiovascular comorbidities. For 
instance, because hypertension might necessitate ACEI/ARB use, and hypertension contributes to 
poor COVID-19 clinical outcomes, estimates that do not adjust for hypertension might be spuriously 
elevated as seen above (an example of “confounding by indication”). Indeed, when subgroup 
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analyses that included only hypertensive patients were conducted, ACEI/ARB exposure was no 
longer associated with susceptibility to infection, hospitalization or disease severity while it 
decreased the odds of dying. Lastly, co-interventions such as steroids and remdesivir that could 
influence these results have not been accounted for since studies rarely reported these co-
interventions and stratified them by cardiovascular drug exposure in our preliminary results.15  
We also reported pooled adjusted estimates in which ACEI/ARB exposure was not associated with 
confirmed COVID-19 infection, hospitalization and disease severity. Xu et al.27 explored two of these 
outcomes (susceptibility to COVID-19 and disease severity) and reported similar results. For all-cause 
mortality, ACEI/ARB exposure was protective based on the adjusted hazards ratios but not with odds 
or risk ratios (Xu et al.27 reported lack of association based on the adjusted odds and hazard ratios 
but their estimates were again based on fewer studies). It is important to note that although pooling 
adjusted estimates can protect against the effect of confounders present in unadjusted estimates, 
these pooled adjusted estimates should still be cautiously interpreted since many did not include 
adjustment for important confounders, and odds/hazard/risk ratios that adjust for different sets of 
covariates may not be comparable.19 Further, adjusted odds/hazards ratios are expected to be 
further from zero (the “non-collapsibility” of effect estimates).28  
Regarding other cardiovascular drug classes, this is the first review to be broad in this context (most 
previous reviews have focused solely on ACEIs/ARBs) with most other drugs not being associated 
with poor COVID-19 clinical outcomes in the pooled adjusted estimates.  One key result is that 
anticoagulants and lipid modifying drugs appear to protect against all-cause mortality based on the 
adjusted hazards ratios, similar to previous reports.29,30 However, the number of included studies (8 
and 7 respectively) was small and the adjusted odds/risk ratios were not statistically significant. The 
potential mechanisms in which cardiovascular drugs can influence COVID-19 outcomes have been 
previously discussed.6,7,9-11  
Limitations of this review 
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For most of the meta-analyses, heterogeneity in effect estimates was high, which is similar to 
previous observations.27,31,32 Consequently, following GRADE rating,23 all estimates with high 
heterogeneity (I2 >70) were downgraded by one level (high to moderate certainty rating). 
Additionally, almost all estimates received quality ratings of either 3 or 4 for including mostly 
observational studies, which we previously ranked to be at a serious risk of bias.15 Again following 
GRADE23 recommendations, the evidence certainty rating was downgraded by one level for 
estimates with a serious risk of bias (from high to moderate or from moderate to low). Based on this 
level of rating, we need to be cautious of over-interpreting both these positive and negative findings. 
Despite our comprehensive search strategy and to facilitate timely publication, we did not contact 
study authors to include potentially eligible studies. We also included several preprint publications 
that have not been certified by peer review. This we felt necessary since many COVID-19 studies are 
being first published as preprints. We tried to exclude potentially overlapping data – however, we 
may have missed some overlapping data or inadvertently excluded non-overlapping data. We also 
relied on single-reviewer extraction for 80% of the studies, which could introduce bias from simple 
errors. The overall low contributions/assigned weights of the individual studies make the reported 
estimates robust to these errors. Additionally, consistency was observed in the 20% records that 
were independently extracted by a second reviewer, with the first reviewer not missing out on key 
studies or crucial information (specifically the quantitative data used in the meta-analyses and the 
information important to assessing the overall rating of individual studies). Lastly, we could not 
explore the interplay of the various cardiovascular drugs because of the insufficient quality of 
included studies. Once more high-quality studies become available (in particular randomized 
controlled studies, RCTs), we will compare how the different drug classes perform in combination 
and against each other. Indeed, in our next update, to be conducted within 6 months of the 
publication of this review, we will focus on RCTs. The COVID-19 situation is extremely dynamic, and 
it is not possible to tell when we will be transitioning out of the living systematic review mode. 
Nevertheless, updating for up to two years is currently planned. 
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Conclusions 
Low- to moderate-certainty evidence suggests that cardiovascular drugs are not associated with 
poor COVID-19 clinical outcomes in high-risk patients such as those with hypertension. For 
ACEIs/ARBs, this is consistent with a recently RCT.33  High quality evidence in the form of more RCTs 
is urgently required and will be the focus of our next systematic review update. As we await further 
evidence, patients on cardiovascular drugs should continue taking their medications as is 
recommended worldwide for ACEIs/ARBs.  
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Primary meta-analysis Hypertensive patients 
Estimate (95%), I2 
Adjusted estimates (95% CI) Reference Figures/ 
Tables Included 
studies  
Sample size Unadjusted estimates 




at risk of 
COVID-19) 
ACEI/ARB 59 48 10,522,649 OR 1.14 (1.00; 1.31), I2=97%, 0.18 OR (n=9): 0.93 (0.79; 1.09), I2=82% OR (n=16): 0.92 (0.71; 1.19), I2=85% 
HR (n=6): 0.88 (0.75; 1.04), I2=76% 
RR (n=7): 0.99 (0.86; 1.14), I2=76% 
Figures 2–3, Figure 
S1 
ACEI 39 31 9,779,752 OR 1.11 (0.96; 1.30), I2=96%, <0.10 OR (n=9): 0.89 (0.77; 1.03), I2=73% OR (n=14): 0.95 (0.79; 1.14), I2=43% 
HR (n=6): 0.81 (0.72; 0.90), I2=59% 
RR (n=5): 0.93 (0.76; 1.14), I2=58% 
Figure S2 
ARB 38 30 9,767,469 OR 1.16 (0.99; 1.36), I2=96%, 0.49 OR (n=9): 1.10 (0.96; 1.26), I2=69% OR (n=13): 0.97 (0.76; 1.25), I2=88% 
HR (n=5): 0.95 (0.70; 1.29), I2=96% 
RR (n=4): 1.09 (0.79; 1.50), I2=85% 
Figure S3 
Anticoagulant 24 24 9,421,814 OR 1.27 (0.87; 1.85), I2=99%, 0.29 Not analysedd OR (n=3): 1.00 (0.59; 1.71), I2=91% 
HR (n=2): 1.30 (1.18; 1.42), I2=0% 
RR (n=2): 1.51 (1.30; 1.75), I2=0% 
Figure S4 
Antiplatelet 18 18 8,952,450 OR 1.13 (0.78; 1.64), I2=99%, 0.13 Not analysedd OR (n=3): 0.78 (0.31; 1.95), I2=87% 
HR (n=2): 1.32 (1.16; 1.50), I2=0% 
RR (n=2): 1.44 (1.22; 1.70), I2=0% 
Figure S5 
Beta blocker 23 19 9,219,560 OR 1.06 (0.82; 1.38), I2=99%, 0.10 OR (n=4): 0.88 (0.75; 1.03), I2=55% OR (n=7): 0.96 (0.88; 1.04), I2=26% 
HR (n=2): 0.98 (0.94; 1.03), I2=0% 
RR (n=4): 1.15 (0.92; 1.44), I2=83% 
Figure S6 
CCB 22 18 9,582,060 OR 1.13 (0.88; 1.45), I2=99%, 0.25 OR (n=5): 1.03 (0.96; 1.11), I2=0% OR (n=7): 1.02 (0.86; 1.20), I2=73% 
HR (n=2): 1.04 (0.77; 1.41), I2=72% 
RR (n=5): 1.04 (0.93; 1.16), I2=0% 
Figure S7 
Diuretic 21 19 13,390,831 OR 1.24 (1.06; 1.44), I2=97%, 0.25 OR (n=4): 1.33 (0.90; 1.95), I2=92% OR (n=7): 0.86 (0.62; 1.19), I2=82% 
HR (n=2): 0.90 (0.53; 1.53), I2=91% 
RR (n=3): 1.51 (0.82; 2.78), I2=99% 
Figure S8 
LMD 22 21 9,549,627 OR 1.04 (0.79; 1.37), I2=99%, <0.10 OR (n=2): 1.20 (0.26; 5.61), I2=93% OR (n=6): 0.85 (0.49; 1.48), I2=86% 
HR (n=2): 0.90 (0.86; 0.94), I2=0% 






ACEI/ARB 31 27 63,132 OR 1.76 (1.34; 2.32), I2=95%, 0.26 OR (n=4): 0.84 (0.58; 1.22), I2=66% OR (n=11): 0.93 (0.70; 1.24), I2=62% 
HR (n=4): 1.08 (0.90; 1.28), I2=63% 
Figures 2–3, Figure 
S10 
ACEI 20 18 45,677 OR 1.64 (1.22; 2.22), I2=92%, 0.98 OR (n=4): 0.73 (0.46; 1.15), I2=29% OR (n=9): 0.83 (0.60; 1.16), I2=58% 
HR (n=3): 1.02 (0.77; 1.35), I2=82% 
Figure S11 
ARB 19 17 45,620 OR 1.45 (1.09; 1.93), I2=90%, 0.87 OR (n=4): 0.86 (0.64; 1.15), I2=29% OR (n=8): 1.04 (0.73; 1.47), I2=61% 
HR (n=3): 1.06 (0.89; 1.27), I2=20% 
Figure S12 
Anticoagulant 12 12 24,770 OR 3.32 (2.20; 5.01), I2=92%, 0.79 Not analysedd NA Figure S13 
Beta blocker 10 9 22,223 OR 2.64 (1.68; 4.14), I2=92%, NA NA OR (n=3): 0.87 (0.38; 2.03), I2=79% Figure S14 
CCB 10 9 43,515 OR 1.85 (1.16; 2.95), I2=96%, NA OR (n=2): 1.49 (0.75; 2.94), I2=0% OR (n=5): 1.03 (0.84; 1.27), I2=0% Figure S15 
LMD 10 9 18,826 OR 3.44 (2.33; 5.10), I2=91%, NA NA OR (n=2): 1.00 (0.31; 3.21), I2=86% Figure S16 
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ACEI/ARB 27 9 1,697 MD -0.27 (-1.36; 0.82) days, 
I2=24%, NA 
MD (n=6): -0.14 (-1.65; 1.36) days, 
I2=0% 
NA Figures 2–3, Figure 
S17 
Anticoagulants 10 10 2,358 MD 3.39 (0.29; 6.48) days, 
I2=80%, NA (2 studies with zero 
weight) 




ACEI/ARB 165 132 182,841 OR 1.40 (1.26; 1.55), I2=87%, 0.74 OR (n=38): 0.92 (0.76; 1.11), I2=72% OR (n=54): 1.05 (0.81; 1.38), I2=85% 
HR (n=14): 0.84 (0.65; 1.10), I2=75% 
RR (n=8): 1.53 (0.54; 4.31), I2=97% 
Figures 2–3, Figure 
S19 
ACEI 83 78 153,113 OR 1.45 (1.27; 1.66), I2=85%, 0.28 OR (n=20): 0.93 (0.77; 1.14), I2=33% OR (n=18): 0.90 (0.67; 1.19), I2=61% 
HR (n=5): 1.07 (0.94; 1.23), I2=47% 
RR (n=4): 0.87 (0.68; 1.11), I2=8% 
Figure S20 
ARB 79 75 145,684 OR 1.36 (1.20; 1.53), I2=83%, 0.97 OR (n=21): 0.85 (0.70; 1.03), I2=55% OR (n=24): 1.13 (0.82; 1.55), I2=62% 
HR (n=6): 0.75 (0.39; 1.44), I2=77% 
RR (n=5): 0.99 (0.82; 1.19), I2=45% 
Figure S21 
Anticoagulant 40 40 66,404 OR 1.59 (1.25; 2.02), I2=88%, 0.21 Not analysedd OR (n=6): 0.84 (0.59; 1.18), I2=69% 
HR (n=3): 0.88 (0.69; 1.12), I2=0% 
RR (n=2): 1.29 (0.74; 2.25), I2=0% 
Figure S22 
Antiplatelet 33 31 50,384 OR 1.29 (1.04; 1.61), I2=85%, 0.29 Not analysedd OR (n=6): 0.69 (0.45; 1.06), I2=37% 
HR (n=3): 0.91 (0.58; 1.43), I2=77% 
RR (n=2): 0.62 (0.36; 1.05), I2=0% 
Figure S23 
Beta blocker 36 32 66,586 OR 1.61 (1.28; 2.03), I2=91%, 0.57 OR (n=10): 1.02 (0.87; 1.20), I2=0% OR (n=9): 1.23 (0.82; 1.85), I2=57% 
HR (n=3): 0.97 (0.72; 1.28), I2=15% 
RR (n=2): 1.02 (0.84; 1.24), I2=0% 
Figure S24 
CCB 38 36 123,756 OR 1.58 (1.27; 1.97), I2=90%, 0.86 OR (n=14): 1.13 (0.98; 1.31), I2=0% OR (n=8): 0.93 (0.56; 1.54), I2=33% 
HR (n=2): 1.15 (0.83; 1.58), I2=77% 
RR (n=3): 1.14 (0.89; 1.46), I2=30% 
Figure S25 
Diuretic 32 29 60,368 OR 1.60 (1.14; 2.24), I2=94%, 0.50 OR (n=8): 0.94 (0.76; 1.15), I2=0% OR (n=7): 0.80 (0.43; 1.47), I2=17% 
HR (n=2): 0.95 (0.75; 1.21), I2=0% 
RR (n=2): 0.85 (0.69; 1.06), I2=0% 
Figure S26 
LMD 42 40 63,456 OR 1.42 (1.18; 1.69), I2=88%, 0.76 OR (n=2): 0.77 (0.11; 5.54), I2=68% OR (n=10): 0.83 (0.56; 1.23), I2=71% 
HR (n=4): 0.95 (0.70; 1.27), I2=78% 
Figure S27 
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ACEI/ARB 163 131 188,944 OR 1.22 (1.12; 1.33), I2=83%, <0.10 OR (n=39): 0.76 (0.65; 0.88), I2=62% OR (n=48): 0.84 (0.70; 1.00), I2=66% 
HR (n=27): 0.76 (0.61; 0.95), I2=78% 
RR (n=10): 0.71 (0.46; 1.09), I2=68% 
Figures 2–3, Figure 
S28 
ACEI 67 63 143,470 OR 1.26 (1.11; 1.43), I2=81%, <0.10 OR (n=18): 0.92 (0.81; 1.06), I2=23% OR (n=17): 0.88 (0.66; 1.17), I2=72% 
HR (n=13): 0.92 (0.73; 1.16), I2=39% 
RR (n=4): 1.08 (0.47; 2.52), I2=50% 
Figure S29 
ARB 66 63 146,614 OR 1.17 (1.05; 1.30), I2=75%, <0.10 OR (n=18): 0.84 (0.68; 1.03), I2=67% OR (n=16): 0.98 (0.73; 1.30), I2=56% 
HR (n=13): 0.67 (0.46; 0.98), I2=81% 
RR (n=3): 1.41 (0.74; 2.69), I2=0% 
Figure S30 
Anticoagulant 82 71 110,049 OR 1.28 (1.05; 1.57), I2=93%, <0.10 Not analysedd OR (n=16): 0.93 (0.61; 1.41), I2=84% 
HR (n=8): 0.54 (0.37; 0.77), I2=85% 
RR (n=4): 1.28 (1.05; 1.56), I2=0% 
Figure S31 
Antiplatelet 50 47 87,328 OR 1.68 (1.38; 2.03), I2=88%, <0.10 Not analysedd OR (n=5): 0.79 (0.48; 1.28), I2=23% 
HR (n=5): 0.74 (0.48; 1.15), I2=62% 
RR (n=3): 0.89 (0.51; 1.53), I2=39% 
Figure S32 
Beta blocker 41 38 63,757 OR 1.87 (1.51; 2.31), I2=87%, <0.10 OR (n=8): 1.17 (0.88; 1.56), I2=33% OR (n=8): 1.15 (0.94; 1.41), I2=54% 
HR (n=3): 1.13 (1.06; 1.21), I2=0% 
RR (n=2): 0.83 (0.47; 1.48), I2=0% 
Figure S33 
CCB 38 32 103,729 OR 1.58 (1.33; 1.88), I2=80%, <0.10 OR (n=11): 0.91 (0.75; 1.10), I2=2% OR (n=7): 1.01 (0.80; 1.27), I2=20% 
HR (n=5): 0.77 (0.35; 1.67), I2=71% 
RR (n=2): 1.45 (0.83; 2.53), I2=0% 
Figure S34 
Diuretic 30 28 85,555 OR 2.46 (1.78; 3.40), I2=94%, <0.10 OR (n=5): 1.01 (0.59; 1.74), I2=64% OR (n=8): 1.44 (1.19; 1.75), I2=1% 
HR (n=6): 0.93 (0.39; 2.21), I2=65% 
Figure S35 
LMD 51 48 111,346 OR 1.39 (1.16; 1.67), I2=92%, <0.10 OR (n=3): 1.01 (0.45; 2.25), I2=66% OR (n=11): 0.88 (0.68; 1.13), I2=72% 
HR (n=7): 0.76 (0.59; 0.98), I2=77% 
RR (n=2): 0.85 (0.35; 2.05), I2=89% 
Figure S36 
aBased on the modified Oxford Centre for Evidence-based Medicine for ratings of individual studies, all pooled estimates received quality ratings of either 3 or 4 for including mostly observational 
studies. In terms of GRADE rating, all estimates were downgraded to moderate certainty due to a serious risk of bias for all. Estimates with heterogeneity (I2 >70) were further downgraded to low 
certainty. bWith reference to studies reporting unadjusted estimates. cA p-value <0.1 was suggestive of publication bias. However, trim and fill random effects analysis revealed that missing trials 
neither changed the direction of the pooled effect estimates nor affected their statistical significance. dAnticoagulants and antiplatelets not primarily used to treat hypertension. Abbreviations: 
ACEI = angiotensin-converting enzyme inhibitor, ARB = angiotensin receptor blocker, CCB = calcium channel blocker, I2 = I-squared (a heterogeneity measure), HR = hazard ratio, LMD = lipid 
modifying drug, MD = mean difference, NA = not applicable, OR = odds ratio, RR = risk ratio. 























Figure 1. PRISMA Flow Chart of Included Studies. Abbreviations: SSRN = Social Science Research 
Network. 
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  Authorea (n = 1,324) 
   medRxiv/bioRxiv (n = 10,090) 
   Preprints.org (n = 1,074) 
   Research square (n = 3,983)  
   SSRN (n = 2,715) 
Full-text records excluded, with 
reasons (n = 4,103) 
No cardiovascular drugs = 3,282 
Association between cardiovascular drugs 
and COVID-19 clinical outcomes not 
reported = 464 
Reviews, editorials, comments etc. = 317 
Duplicate studies = 27 
Other reasons = 13 
Poster identified from another 
systematic review (n = 1) 
Studies included in quantitative 
synthesis (n = 390)  
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Figure 2. Forest plots for associations between COVID-19 outcomes and being on an angiotensin-
converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB). 
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Figure 3. Forest plots for associations between COVID-19 outcomes and being on an angiotensin-
converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) – only hypertensive 
patients included. 
 
